Evidence map›Paper›PMID 33571426›Full record

ReviewCell2021

Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics.

Xiao Tan, Justin H Letendre, James J Collins, Wilson W Wong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Logic-Gated HSV-TK/GCV Suicide Gene Circuit for Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  11. Article
  12. Article
  13. Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao TanWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA; Division of Gastroenterology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA; Institute for Medical Engineering and Science, MIT, Cambridge, MA 02139, USA.
Justin H LetendreDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Biological Design Center, Boston University, Boston, MA 02215, USA.
James J CollinsWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA; Institute for Medical Engineering and Science, MIT, Cambridge, MA 02139, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA; Synthetic Biology Center, MIT, 77 Massachusetts Ave., Cambridge, MA 02139, USA; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: jimjc@mit.edu.
Wilson W WongDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Biological Design Center, Boston University, Boston, MA 02215, USA. Electronic address: wilwong@bu.edu.

Funding

Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Synthetically Reengineered T cells as the Next Generation of Smart Cancer TherapyDP2CA186574 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2013 to 2013
$2.5M
Advanced recombinase-based gene expression technology in mammalian cellsR01GM129011 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI WONG, WILSON · 2019 to 2022
$1.5M
Engineering a smart CAR platform for human regulatory T cellsR56EB027729 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI DOOMS, HANS PETER, EMILI, ANDREW · 2019 to 2019
$357k
Advanced Recombinase Technology for Tissue Engineering ApplicationsF31HL149334 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI LETENDRE, JUSTIN HENRY · 2019 to 2021
$88k
NCI NIH HHS DP2 CA186574NHLBI NIH HHS F31 HL149334NIBIB NIH HHS R01 EB029483NIBIB NIH HHS R56 EB027729NIGMS NIH HHS R01 GM129011
6 · The paper itself

Abstract

Synthetic biology is a design-driven discipline centered on engineering novel biological functions through the discovery, characterization, and repurposing of molecular parts. Several synthetic biological solutions to critical biomedical problems are on the verge of widespread adoption and demonstrate the burgeoning maturation of the field. Here, we highlight applications of synthetic biology in vaccine development, molecular diagnostics, and cell-based therapeutics, emphasizing technologies approved for clinical use or in active clinical trials. We conclude by drawing attention to recent innovations in synthetic biology that are likely to have a significant impact on future applications in biomedicine.

Indexed as

Biomedical ResearchGenetic EngineeringSynthetic BiologyAnimalsCRISPR-Cas SystemsHumansRNAVaccinesRNAVaccines

Identifiers

PMID33571426
PMCPMC7897318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.